Childhood cancer survival in Europe

G. Gatta, I. Corazziari, C. Magnani, R. Peris-Bonet, P. Roazzi, C. Stiller, W. Oberaigner, M. Jechova, M. Rousarova, H. H. Storm, T. Aareleid, T. Hakulinen, G. Hédelin, I. Tron, E. Le Gall, G. Launoy, I. Macé-Lesech, I. Faivre, G. Chaplain, P. M. CarliB. Lacour, N. Raverdy, C. Berger, F. Freycon, P. Grosclaude, I. Estève, P. Kaatsch, L. Tryggvadottir, F. Berrino, C. Allemani, P. Baili, L. Ciccolallo, G. Gatta, A. Micheli, M. Sant, E. Taussig, R. Capocaccia, E. Carrani, R. De Angelis, S. Hartley, P. Roazzi, M. Santaquilani, A. Tavilla, F. Valente, A. Verdecchia, S. Ferretti, P. Crosignani, G. Tagliabue, E. Conti, M. Vercelli, F. Pannelli, P. Mosciatti, M. Federico, M. E. Artioli, V. De Lisi, L. Serventi, C. Magnani, G. Pastore, L. Gafà, R. Tumino, F. Falcini, M. Budroni, E. Paci, E. Crocetti, P. Zambon, S. Guzzinati, M. Dalmas, F. Langmark, A. Andersen, J. Rachtan, M. Bielska-Lasota, Z. Wronkowski, M. Zwierko, I. Pleško, A. Obsitníková, V. Pompe-Kirn, I. Izarzugaza, C. Martinez-Garcia, I. Garau, C. Navarro, M. D. Chirlaque, E. Ardanaz, C. Moreno, J. Galceran, A. Torrella, L. Barlow, T. Möller, J. M. Lutz, M. Usel, J. W W Coebergh, A. Van Der Does-Van Den Berg, O. Visser, M. P. Coleman, C. Stiller, R. Black, D. Brewster

Research output: Contribution to journalArticle

Abstract

Background: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. Methods: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. Results: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (≥75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. Conclusions: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

Original languageEnglish
JournalAnnals of Oncology
Volume14
Issue numberSUPPL.5
DOIs
Publication statusPublished - 2003

Fingerprint

Scandinavian and Nordic Countries
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System Neoplasms
Neoplasms
Wilms Tumor
Estonia
Iceland
Eastern Europe
Denmark
Switzerland
Hodgkin Disease
Non-Hodgkin's Lymphoma
Population
Germany
Registries
Therapeutics
Referral and Consultation

Keywords

  • Childhood tumours
  • Europe
  • Population-based study
  • Survival variation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gatta, G., Corazziari, I., Magnani, C., Peris-Bonet, R., Roazzi, P., Stiller, C., ... Brewster, D. (2003). Childhood cancer survival in Europe. Annals of Oncology, 14(SUPPL.5). https://doi.org/10.1093/annonc/mdg755

Childhood cancer survival in Europe. / Gatta, G.; Corazziari, I.; Magnani, C.; Peris-Bonet, R.; Roazzi, P.; Stiller, C.; Oberaigner, W.; Jechova, M.; Rousarova, M.; Storm, H. H.; Aareleid, T.; Hakulinen, T.; Hédelin, G.; Tron, I.; Le Gall, E.; Launoy, G.; Macé-Lesech, I.; Faivre, I.; Chaplain, G.; Carli, P. M.; Lacour, B.; Raverdy, N.; Berger, C.; Freycon, F.; Grosclaude, P.; Estève, I.; Kaatsch, P.; Tryggvadottir, L.; Berrino, F.; Allemani, C.; Baili, P.; Ciccolallo, L.; Gatta, G.; Micheli, A.; Sant, M.; Taussig, E.; Capocaccia, R.; Carrani, E.; De Angelis, R.; Hartley, S.; Roazzi, P.; Santaquilani, M.; Tavilla, A.; Valente, F.; Verdecchia, A.; Ferretti, S.; Crosignani, P.; Tagliabue, G.; Conti, E.; Vercelli, M.; Pannelli, F.; Mosciatti, P.; Federico, M.; Artioli, M. E.; De Lisi, V.; Serventi, L.; Magnani, C.; Pastore, G.; Gafà, L.; Tumino, R.; Falcini, F.; Budroni, M.; Paci, E.; Crocetti, E.; Zambon, P.; Guzzinati, S.; Dalmas, M.; Langmark, F.; Andersen, A.; Rachtan, J.; Bielska-Lasota, M.; Wronkowski, Z.; Zwierko, M.; Pleško, I.; Obsitníková, A.; Pompe-Kirn, V.; Izarzugaza, I.; Martinez-Garcia, C.; Garau, I.; Navarro, C.; Chirlaque, M. D.; Ardanaz, E.; Moreno, C.; Galceran, J.; Torrella, A.; Barlow, L.; Möller, T.; Lutz, J. M.; Usel, M.; Coebergh, J. W W; Van Der Does-Van Den Berg, A.; Visser, O.; Coleman, M. P.; Stiller, C.; Black, R.; Brewster, D.

In: Annals of Oncology, Vol. 14, No. SUPPL.5, 2003.

Research output: Contribution to journalArticle

Gatta, G, Corazziari, I, Magnani, C, Peris-Bonet, R, Roazzi, P, Stiller, C, Oberaigner, W, Jechova, M, Rousarova, M, Storm, HH, Aareleid, T, Hakulinen, T, Hédelin, G, Tron, I, Le Gall, E, Launoy, G, Macé-Lesech, I, Faivre, I, Chaplain, G, Carli, PM, Lacour, B, Raverdy, N, Berger, C, Freycon, F, Grosclaude, P, Estève, I, Kaatsch, P, Tryggvadottir, L, Berrino, F, Allemani, C, Baili, P, Ciccolallo, L, Gatta, G, Micheli, A, Sant, M, Taussig, E, Capocaccia, R, Carrani, E, De Angelis, R, Hartley, S, Roazzi, P, Santaquilani, M, Tavilla, A, Valente, F, Verdecchia, A, Ferretti, S, Crosignani, P, Tagliabue, G, Conti, E, Vercelli, M, Pannelli, F, Mosciatti, P, Federico, M, Artioli, ME, De Lisi, V, Serventi, L, Magnani, C, Pastore, G, Gafà, L, Tumino, R, Falcini, F, Budroni, M, Paci, E, Crocetti, E, Zambon, P, Guzzinati, S, Dalmas, M, Langmark, F, Andersen, A, Rachtan, J, Bielska-Lasota, M, Wronkowski, Z, Zwierko, M, Pleško, I, Obsitníková, A, Pompe-Kirn, V, Izarzugaza, I, Martinez-Garcia, C, Garau, I, Navarro, C, Chirlaque, MD, Ardanaz, E, Moreno, C, Galceran, J, Torrella, A, Barlow, L, Möller, T, Lutz, JM, Usel, M, Coebergh, JWW, Van Der Does-Van Den Berg, A, Visser, O, Coleman, MP, Stiller, C, Black, R & Brewster, D 2003, 'Childhood cancer survival in Europe', Annals of Oncology, vol. 14, no. SUPPL.5. https://doi.org/10.1093/annonc/mdg755
Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, Stiller C et al. Childhood cancer survival in Europe. Annals of Oncology. 2003;14(SUPPL.5). https://doi.org/10.1093/annonc/mdg755
Gatta, G. ; Corazziari, I. ; Magnani, C. ; Peris-Bonet, R. ; Roazzi, P. ; Stiller, C. ; Oberaigner, W. ; Jechova, M. ; Rousarova, M. ; Storm, H. H. ; Aareleid, T. ; Hakulinen, T. ; Hédelin, G. ; Tron, I. ; Le Gall, E. ; Launoy, G. ; Macé-Lesech, I. ; Faivre, I. ; Chaplain, G. ; Carli, P. M. ; Lacour, B. ; Raverdy, N. ; Berger, C. ; Freycon, F. ; Grosclaude, P. ; Estève, I. ; Kaatsch, P. ; Tryggvadottir, L. ; Berrino, F. ; Allemani, C. ; Baili, P. ; Ciccolallo, L. ; Gatta, G. ; Micheli, A. ; Sant, M. ; Taussig, E. ; Capocaccia, R. ; Carrani, E. ; De Angelis, R. ; Hartley, S. ; Roazzi, P. ; Santaquilani, M. ; Tavilla, A. ; Valente, F. ; Verdecchia, A. ; Ferretti, S. ; Crosignani, P. ; Tagliabue, G. ; Conti, E. ; Vercelli, M. ; Pannelli, F. ; Mosciatti, P. ; Federico, M. ; Artioli, M. E. ; De Lisi, V. ; Serventi, L. ; Magnani, C. ; Pastore, G. ; Gafà, L. ; Tumino, R. ; Falcini, F. ; Budroni, M. ; Paci, E. ; Crocetti, E. ; Zambon, P. ; Guzzinati, S. ; Dalmas, M. ; Langmark, F. ; Andersen, A. ; Rachtan, J. ; Bielska-Lasota, M. ; Wronkowski, Z. ; Zwierko, M. ; Pleško, I. ; Obsitníková, A. ; Pompe-Kirn, V. ; Izarzugaza, I. ; Martinez-Garcia, C. ; Garau, I. ; Navarro, C. ; Chirlaque, M. D. ; Ardanaz, E. ; Moreno, C. ; Galceran, J. ; Torrella, A. ; Barlow, L. ; Möller, T. ; Lutz, J. M. ; Usel, M. ; Coebergh, J. W W ; Van Der Does-Van Den Berg, A. ; Visser, O. ; Coleman, M. P. ; Stiller, C. ; Black, R. ; Brewster, D. / Childhood cancer survival in Europe. In: Annals of Oncology. 2003 ; Vol. 14, No. SUPPL.5.
@article{4476fec846c64f1bb57c224853a9084b,
title = "Childhood cancer survival in Europe",
abstract = "Background: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. Methods: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. Results: For all cancers combined, survival variation was large (45{\%} in Estonia to 90{\%} in Iceland), and was generally low (60-70{\%}) in eastern Europe and high (≥75{\%}) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92{\%}), acute lymphoid leukaemia (85{\%}), CNS tumours (73{\%}) and acute non-lymphocytic leukaemia (62{\%}). The eastern countries had lowest survival: 89{\%} for Hodgkin's disease, 71{\%} for nephroblastoma, 68{\%} for acute lymphoid leukaemia, 61{\%} for non-Hodgkin's lymphoma, 57{\%} for central nervous system (CNS) tumours and 29{\%} for acute non-lymphocytic leukaemia. Conclusions: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.",
keywords = "Childhood tumours, Europe, Population-based study, Survival variation",
author = "G. Gatta and I. Corazziari and C. Magnani and R. Peris-Bonet and P. Roazzi and C. Stiller and W. Oberaigner and M. Jechova and M. Rousarova and Storm, {H. H.} and T. Aareleid and T. Hakulinen and G. H{\'e}delin and I. Tron and {Le Gall}, E. and G. Launoy and I. Mac{\'e}-Lesech and I. Faivre and G. Chaplain and Carli, {P. M.} and B. Lacour and N. Raverdy and C. Berger and F. Freycon and P. Grosclaude and I. Est{\`e}ve and P. Kaatsch and L. Tryggvadottir and F. Berrino and C. Allemani and P. Baili and L. Ciccolallo and G. Gatta and A. Micheli and M. Sant and E. Taussig and R. Capocaccia and E. Carrani and {De Angelis}, R. and S. Hartley and P. Roazzi and M. Santaquilani and A. Tavilla and F. Valente and A. Verdecchia and S. Ferretti and P. Crosignani and G. Tagliabue and E. Conti and M. Vercelli and F. Pannelli and P. Mosciatti and M. Federico and Artioli, {M. E.} and {De Lisi}, V. and L. Serventi and C. Magnani and G. Pastore and L. Gaf{\`a} and R. Tumino and F. Falcini and M. Budroni and E. Paci and E. Crocetti and P. Zambon and S. Guzzinati and M. Dalmas and F. Langmark and A. Andersen and J. Rachtan and M. Bielska-Lasota and Z. Wronkowski and M. Zwierko and I. Pleško and A. Obsitn{\'i}kov{\'a} and V. Pompe-Kirn and I. Izarzugaza and C. Martinez-Garcia and I. Garau and C. Navarro and Chirlaque, {M. D.} and E. Ardanaz and C. Moreno and J. Galceran and A. Torrella and L. Barlow and T. M{\"o}ller and Lutz, {J. M.} and M. Usel and Coebergh, {J. W W} and {Van Der Does-Van Den Berg}, A. and O. Visser and Coleman, {M. P.} and C. Stiller and R. Black and D. Brewster",
year = "2003",
doi = "10.1093/annonc/mdg755",
language = "English",
volume = "14",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL.5",

}

TY - JOUR

T1 - Childhood cancer survival in Europe

AU - Gatta, G.

AU - Corazziari, I.

AU - Magnani, C.

AU - Peris-Bonet, R.

AU - Roazzi, P.

AU - Stiller, C.

AU - Oberaigner, W.

AU - Jechova, M.

AU - Rousarova, M.

AU - Storm, H. H.

AU - Aareleid, T.

AU - Hakulinen, T.

AU - Hédelin, G.

AU - Tron, I.

AU - Le Gall, E.

AU - Launoy, G.

AU - Macé-Lesech, I.

AU - Faivre, I.

AU - Chaplain, G.

AU - Carli, P. M.

AU - Lacour, B.

AU - Raverdy, N.

AU - Berger, C.

AU - Freycon, F.

AU - Grosclaude, P.

AU - Estève, I.

AU - Kaatsch, P.

AU - Tryggvadottir, L.

AU - Berrino, F.

AU - Allemani, C.

AU - Baili, P.

AU - Ciccolallo, L.

AU - Gatta, G.

AU - Micheli, A.

AU - Sant, M.

AU - Taussig, E.

AU - Capocaccia, R.

AU - Carrani, E.

AU - De Angelis, R.

AU - Hartley, S.

AU - Roazzi, P.

AU - Santaquilani, M.

AU - Tavilla, A.

AU - Valente, F.

AU - Verdecchia, A.

AU - Ferretti, S.

AU - Crosignani, P.

AU - Tagliabue, G.

AU - Conti, E.

AU - Vercelli, M.

AU - Pannelli, F.

AU - Mosciatti, P.

AU - Federico, M.

AU - Artioli, M. E.

AU - De Lisi, V.

AU - Serventi, L.

AU - Magnani, C.

AU - Pastore, G.

AU - Gafà, L.

AU - Tumino, R.

AU - Falcini, F.

AU - Budroni, M.

AU - Paci, E.

AU - Crocetti, E.

AU - Zambon, P.

AU - Guzzinati, S.

AU - Dalmas, M.

AU - Langmark, F.

AU - Andersen, A.

AU - Rachtan, J.

AU - Bielska-Lasota, M.

AU - Wronkowski, Z.

AU - Zwierko, M.

AU - Pleško, I.

AU - Obsitníková, A.

AU - Pompe-Kirn, V.

AU - Izarzugaza, I.

AU - Martinez-Garcia, C.

AU - Garau, I.

AU - Navarro, C.

AU - Chirlaque, M. D.

AU - Ardanaz, E.

AU - Moreno, C.

AU - Galceran, J.

AU - Torrella, A.

AU - Barlow, L.

AU - Möller, T.

AU - Lutz, J. M.

AU - Usel, M.

AU - Coebergh, J. W W

AU - Van Der Does-Van Den Berg, A.

AU - Visser, O.

AU - Coleman, M. P.

AU - Stiller, C.

AU - Black, R.

AU - Brewster, D.

PY - 2003

Y1 - 2003

N2 - Background: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. Methods: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. Results: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (≥75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. Conclusions: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

AB - Background: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. Methods: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. Results: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (≥75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. Conclusions: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

KW - Childhood tumours

KW - Europe

KW - Population-based study

KW - Survival variation

UR - http://www.scopus.com/inward/record.url?scp=1642264515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642264515&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg755

DO - 10.1093/annonc/mdg755

M3 - Article

C2 - 14684502

AN - SCOPUS:1642264515

VL - 14

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL.5

ER -